Inter-organ communication in the regulation of lipid metabolism: Focusing on the network between the liver, intestine, and heart

Journal of Pharmacological Sciences

Volumn 123, Issue 4, 2013, Pages 312-317

  Ito, Masanori ^a   Adachi Akahane, Satomi ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart; Inter organ communication; Intestine; Lipid metabolism; Liver

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BILE ACID; CARNITINE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; VITAMIN;

ATHEROSCLEROSIS; CELL COMMUNICATION; HEART; HUMAN; INTER ORGAN COMMUNICATION; INTESTINE; INTESTINE FLORA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; LIVER FUNCTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW;

BILE ACIDS AND SALTS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; ENERGY METABOLISM; FATTY ACID TRANSPORT PROTEINS; FATTY ACIDS; GENE EXPRESSION; HUMANS; INTESTINES; LIGANDS; LIPID METABOLISM; LIVER; MICRORNAS; PHOSPHATIDYLCHOLINES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84892665500     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13R09CP     Document Type: Review

References (36)

1. Kazantzis M, Stahl A. Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta. 2012;1821:852-857.
2. Miyauchi S, Hirasawa A, Ichimura A, Hara T, Tsujimoto G. New frontiers in gut nutrient sensor research: free fatty acid sensing in the gastrointestinal tract. J Pharmacol Sci. 2010;112:19-24.
3. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013;145:396-406.
4. Bellahcene M, O'Dowd JF, Wargent ET, Zaibi MS, Hislop DC, Ngala RA, et al. Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content. Br J Nutr. 2013;109:1755-1764.
5. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940-948.
6. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239-250.
7. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107-110.
8. de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á, Esau C, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013;112:1602-1612.
9. Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013;127:2097-2106.
10. Van Aelst LN, Heymans S. MicroRNAs as Biomarkers for Ischemic Heart Disease. J Cardiovasc Transl Res. 2013;6:458-470.
11. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262-1267.
12. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17:323-333.
13. Sinha J, Chen F, Miloh T, Burns RC, Yu Z, Shneider BL. beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. Am J Physiol Gastrointest Liver Physiol. 2008;295:G996-G1003.
14. Ito M, Yamanashi Y, Toyoda Y, Izumi-Nakaseko H, Oda S, Sugiyama A, et al. Disruption of Stard10 gene alters the PPARα-mediated bile acid homeostasis. Biochim Biophys Acta. 2013;1831:459-468.
15. Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012;302:E68-E76.
16. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007;23:46-52.
17. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem. 2012;23:203-208.
18. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51:1101-1112.
19. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009;138:476-488.
20. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A. 2011;108:4523-4530.
21. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24:537-545.
22. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97-101.
23. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829.
24. Mukhopadhyay R. Mouse models of atherosclerosis: explaining critical roles of lipid metabolism and inflammation. J Appl Genet. 2013;54:185-192.
25. Superko HR, Pendyala L, Williams PT, Momary KM, King SB 3rd, Garrett BC. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012;6:496-523.
26. Berrougui H, Momo CN, Khalil A. Health benefits of high-density lipoproteins in preventing cardiovascular diseases. J Clin Lipidol. 2012;6:524-533.
27. Maejima T, Sugano T, Yamazaki H, Yoshinaka Y, Doi T, Tanabe S, et al. Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARα-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells. J Pharmacol Sci. 2011;116:107-115.
28. Sahebkar A. Fat lowers fat: purified phospholipids as emerging therapies for dyslipidemia. Biochim Biophys Acta. 2013;1831:887-893.
29. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33:1190-1200.
30. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2013. [Epub ahead of print]
31. Yamada T, Kotake Y, Nagata H, Takeda J. Atrial natriuretic peptide reduces hepatic ischemia-reperfusion injury in rabbits. J Anesth. 2013. [Epub ahead of print]
32. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-585.
33. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57-63.
34. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575-1584.
35. Wang D, Xia M, Yan X, Li D, Wang L, Xu Y, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res. 2012;111:967-981.
36. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567-575.